BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34949662)

  • 1. Molecular Markers for Long-term Survival in Stage IIIA (N2) NSCLC Patients.
    Nastase A; Dima SO; Lupo A; Laszlo V; Tagett R; Draghici S; Georgescu ME; Nechifor A; Berbece S; Popescu I; Alifano M; Klepetko W; Grigoroiu M
    Cancer Genomics Proteomics; 2022; 19(1):94-104. PubMed ID: 34949662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinum Drug Sensitivity Polymorphisms in Stage III Non-small Cell Lung Cancer With Invasion of Mediastinal Lymph Nodes.
    Nastase A; Lupo A; Laszlo V; Damotte D; Dima S; Canny E; Alifano M; Popescu I; Klepetko W; Grigoroiu M
    Cancer Genomics Proteomics; 2020; 17(5):587-595. PubMed ID: 32859637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study.
    Duan H; Liang L; Xie S; Wang C
    BMC Cancer; 2020 Aug; 20(1):809. PubMed ID: 32847544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
    Xu YP; Li B; Xu XL; Mao WM
    Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding Radiotherapy to Adjuvant Chemotherapy Does Not Improve Survival of Patients With N2 Lung Cancer.
    Drake JA; Portnoy DC; Tauer K; Weksler B
    Ann Thorac Surg; 2018 Oct; 106(4):959-965. PubMed ID: 29856974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between circulating lung-specific X protein messenger ribonucleic acid expression and micrometastasis and prognosis in patients with early-stage nonsmall cell lung cancer.
    Cui Y; Wang W; Yao S; Qiu Z; Cong L
    J Cancer Res Ther; 2020; 16(7):1641-1647. PubMed ID: 33565511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
    Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
    Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical benefit of neoadjuvant chemoradiotherapy for the avoidance of pneumonectomy; assessment in 12 consecutive centrally located non-small cell lung cancers.
    Misumi K; Harada H; Tsubokawa N; Tsutani Y; Matsumoto K; Miyata Y; Yamashita Y; Okada M
    Gen Thorac Cardiovasc Surg; 2017 Jul; 65(7):392-399. PubMed ID: 28432576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival.
    Bueno R; Richards WG; Swanson SJ; Jaklitsch MT; Lukanich JM; Mentzer SJ; Sugarbaker DJ
    Ann Thorac Surg; 2000 Dec; 70(6):1826-31. PubMed ID: 11156079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
    Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
    J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperfractionated irradiation with 3 cycles of induction chemotherapy in stage IIIA-N2 lung cancer.
    Chen F; Okubo K; Sonobe M; Shibuya K; Matsuo Y; Kim YH; Yanagihara K; Bando T; Date H
    World J Surg; 2012 Dec; 36(12):2858-64. PubMed ID: 22926283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
    Yang H; Wang K; Li S; Li Y; Yuan L
    Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
    [No Abstract]   [Full Text] [Related]  

  • 14. Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).
    Couñago F; Rodriguez de Dios N; Montemuiño S; Jové-Teixidó J; Martin M; Calvo-Crespo P; López-Mata M; Samper-Ots MP; López-Guerra JL; García-Cañibano T; Díaz-Díaz V; de Ingunza-Barón L; Murcia-Mejía M; Alcántara P; Corona J; Puertas MM; Chust M; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Thuissard IJ; Sanz-Rosa D; Taboada B
    Lung Cancer; 2018 Apr; 118():119-127. PubMed ID: 29571989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of surgical treatment after neoadjuvant chemotherapy for stage III non-small cell lung cancer.
    Carretta A; Ciriaco P; Melloni G; Sayed I; Bandiera A; Ferla L; Puglisi A; Zannini P
    World J Surg; 2008 Dec; 32(12):2636-42. PubMed ID: 18836761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
    Couñago F; Montemuiño S; Martin M; Taboada B; Calvo-Crespo P; Samper-Ots MP; Alcántara P; Corona J; López-Guerra JL; Murcia-Mejía M; López-Mata M; Jové-Teixidó J; Chust M; Díaz-Díaz V; de Ingunza-Barón L; García-Cañibano T; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Puertas MM; Thuissard IJ; Sanz-Rosa D; de Dios NR
    Clin Transl Oncol; 2019 Jun; 21(6):735-744. PubMed ID: 30430394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.
    Gupta AR; Woodard GA; Jablons DM; Mann MJ; Kratz JR
    Future Oncol; 2021 Dec; 17(34):4785-4795. PubMed ID: 34435876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR).
    Reymen B; van Baardwijk A; Wanders R; Borger J; Dingemans AM; Bootsma G; Pitz C; Lunde R; Geraedts W; Lambin P; De Ruysscher D
    Radiother Oncol; 2014 Mar; 110(3):482-7. PubMed ID: 24444527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.
    Wang YD; Ha MW; Cheng J; Zhang WL; Cong X; Tong CY; Sun J
    Oncol Rep; 2012 Apr; 27(4):979-86. PubMed ID: 22179630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided.
    Kappers I; van Sandick JW; Burgers SA; Belderbos JS; van Zandwijk N; Klomp HM
    Lung Cancer; 2010 May; 68(2):222-7. PubMed ID: 19664843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.